Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 13 Sept 2026Clinical review pending
Saved on this device
!
Reverse in parallel with brain rescue
Anticoagulant-associated intracranial haemorrhage can expand quickly; reversal must begin from the exact agent and exposure while airway, blood pressure, CT, critical care and neurosurgical decisions continue.
Action: Stop the anticoagulant, establish the drug, dose and last administration, send urgent haemostasis and renal tests, contact haematology/pharmacy and give the current locally authorised agent-specific reversal without waiting for deterioration or routine laboratory normalisation.
Synopsis
Initiate drug-specific haemostatic treatment for life-threatening intracranial bleeding while preserving urgent neurological care, recognising UK authorisation and access boundaries, and planning monitored anticoagulation restart.
Treat anticoagulant-associated intracranial haemorrhage as simultaneous neurological and haemostatic emergencies: stop exposure, stabilise, image, reverse and seek specialist source control.
Identify the exact medicine, indication, dose, last administration, renal function, weight and interacting drugs; warfarin, dabigatran, factor Xa inhibitors and heparins are not interchangeable.
Match reversal to mechanism: PCC plus intravenous vitamin K for VKA; idarucizumab for dabigatran; selective UK-policy-directed andexanet or off-label PCC assessment for apixaban/rivaroxaban; protamine for recent heparin exposure.
Key red flags
Falling consciousness, worsening focal deficit, new anisocoria or haematoma expansion requires immediate neurocritical and neurosurgical action even while reversal is being prepared.
The phrase 'DOAC' is insufficient: dabigatran and factor Xa inhibitors use different assays and specific antidotes, and renal clearance changes the likely residual effect.
Routine coagulation tests do not provide a universal measure for every direct oral anticoagulant; interpret testing from the identified drug, timing, renal function and a validated drug-specific assay where available.
Andexanet retains UK marketing authorisation for adults with life-threatening or uncontrolled apixaban- or rivaroxaban-associated bleeding, but BSH 2026 warns that increased thrombosis, particularly ischaemic stroke, may outweigh benefit and NHS access differs by jurisdiction.
Every reversal agent carries thrombosis or rebound-anticoagulation concerns; these require monitoring and a later restart plan, not delay of haemostasis in active intracranial bleeding.
Antiplatelet exposure is a separate problem and routine platelet transfusion is not a generic substitute for anticoagulant reversal.
Expanding haemorrhage
Worsening deficit, consciousness or pupils and increased blood on repeat imaging indicate failed control and demand escalation of both haemostatic and neurosurgical treatment.
Reversal complication
Chest pain, limb ischaemia, hypoxaemia, new focal deficit or circuit thrombosis after reversal raises concern for arterial or venous thromboembolism and needs urgent assessment.
Reasoning priorities
01
Immediate non-contrast CT head
Define site, volume, mass effect, intraventricular extension and surgical urgency before and during reversal.
Expansion or new hydrocephalus changes neurological treatment; a stable initial scan does not exclude later growth during residual anticoagulant effect.
Worked reasoning
Worked case: emergency reversalReverse the identified anticoagulant
Acute intracranial haemorrhage is confirmed or strongly suspected in a person with potentially active anticoagulant exposure.
Stop further anticoagulant and activate stroke, neurosurgical, critical-care, haematology, transfusion and pharmacy support while securing airway, circulation, blood pressure and immediate CT.
Establish the exact medicine, dose, last administration, indication, renal function, weight and interacting drugs; send INR, APTT, fibrinogen, blood count, renal tests and drug-specific assays when rapidly available without delaying indicated reversal.
For warfarin give urgent four-factor PCC plus intravenous vitamin K according to presenting INR and the current authorised protocol; for dabigatran use idarucizumab when clinically relevant activity is likely.
For apixaban or rivaroxaban apply the current nation-specific and local specialist pathway, weighing BSH's 2026 thrombotic warning; if andexanet is considered, verify eligibility and do not derive a dose when the last dose amount or timing is unknown, because the UK SmPC provides none.
For recent unfractionated or low-molecular-weight heparin calculate protamine from agent, dose and elapsed time, recognising incomplete LMWH neutralisation; manage antiplatelet exposure through its separate evidence-based pathway.
Reassess examination, imaging and drug-appropriate haemostasis after treatment, escalate expansion or herniation, monitor for thrombosis and document an interim thromboprophylaxis and anticoagulation-restart plan.
Key medicines
Four-factor prothrombin complex concentrate plus intravenous phytomenadioneUse the current UK product and local major-haemorrhage protocol, calculating PCC from presenting INR and weight and giving intravenous vitamin K concurrently for sustained VKA reversal.Verify INR response, avoid unnecessary repeat PCC, watch for thrombosis and volume issues, and remember that vitamin K alone is too slow for immediate haemostasis.
IdarucizumabFor adult emergency reversal of clinically relevant dabigatran effect, give 5 g intravenously as two consecutive 2.5 g/50 mL vials, each over 5–10 minutes or as a bolus, using current product information.It does not reverse factor Xa inhibitors or warfarin; reassess bleeding and coagulation for recurrent activity, particularly with renal failure, and reserve a second 5 g dose for the SmPC's conditional recurrent-activity situations.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.
BSH guideline on bleeding in patients on antithrombotic agentsUK professional guidance dated 1 November 2012 with BSH review recorded 2 June 2019; Table 1 and UFH/LMWH and VKA sections read 13 September 2026. Used only for established VKA and heparin principles; historical statements predating specific DOAC antidotes are superseded.
BSH 2026 position statement on andexanet alfaFull UK professional position body published 25 April 2026, recommendations read 13 September 2026. Warns that increased thrombosis, particularly ischaemic stroke, may outweigh benefit; it does not revoke the UK licence or decide local commissioning.
NICE TA697 andexanet alfa recommendationsTechnology appraisal recommendations published 12 May 2021 and checked 13 September 2026. Recommends andexanet only for reversing apixaban or rivaroxaban in adults with life-threatening or uncontrolled gastrointestinal bleeding; it does not recommend NHS use for intracranial haemorrhage in its jurisdiction.
NICE TA1029 terminated intracranial andexanet appraisalTerminated appraisal status checked 13 September 2026. The absence of a NICE intracranial recommendation is recorded as a commissioning boundary, not misrepresented as cancellation of UK marketing authorisation or a universal prohibition.
Praxbind UK summary of product characteristicsUK SmPC updated 17 January 2025; sections 4.1–4.4 read 13 September 2026 for the adult dabigatran emergency indication, 5 g administration, recurrent-activity provision and monitoring. It does not establish lesion-specific anticoagulation restart timing.
Ondexxya UK summary of product characteristicsUK SmPC updated 5 March 2026; sections 4.1–4.4 and ANNEXA-I population read 13 September 2026. Adult apixaban/rivaroxaban licence only; no dose recommendation if last amount or interval is unknown, anti-Xa assay and heparin-resistance cautions; commissioning and stock are separate.
National Clinical Guideline for Stroke: acute careUK and Ireland stroke guideline 2023, recommendations 3.6A–B and evidence-to-recommendation text read 13 September 2026. Supports VKA and dabigatran reversal in acute spontaneous ICH; its older andexanet trial-only wording is superseded by current BSH and product information.
ESO–EANS guideline on spontaneous intracerebral haemorrhageEuropean adult spontaneous-ICH guideline published 22 May 2025; oral anticoagulant reversal recommendations read 13 September 2026. Used for uncertain PCC and andexanet net benefit and antiplatelet separation; it does not cover trauma, paediatric bleeding or UK access.